Mannitol is named as an intervention in 10 current clinical trials in our Belgium, Canada, Egypt, Spain, Italy, Sweden, Poland, Netherlands, Switzerland, Turkey and Taiwan registers. 7 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is NTC srl (1). The most-studied condition is Elective Colonoscopy. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Mannitol. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Sublingual Birch Immunotherapy for Pollen-associated Food Allergy
2025-523653-34-00 · CTIS ↗ · Immune System Diseases
|
Phase 2 | Authorised | Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) | Germany |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
4 single-substance products containing Mannitol on the HPRA medicines list.
| Condition (as registered) | Trials |
|---|---|
| Elective Colonoscopy | 1 |
| Congenital Heart Disease in Children | 1 |
| Neuroprotection | 1 |
| Functional Dyspepsia | 1 |
| Ischemic Stroke | 1 |
| Stroke | 1 |
| Stroke Acute | 1 |
| Mannitol Adverse Reaction | 1 |
| Delayed Graft Function | 1 |
| Kidney Transplantation | 1 |
| Ototoxic Hearing Loss | 1 |
| Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 1 |
| Mild Traumatic Brain Injury | 1 |
| Moderate Traumatic Brain Injury (TBI) | 1 |
| TBI (Traumatic Brain Injury) | 1 |
| ICP (Intracranial Pressure) Increase | 1 |
| Optic Nerve Sheath Diameter Measurement | 1 |
| Lead sponsor | Trials |
|---|---|
| NTC srl | 1 |
| dr. M.J.N.L. Benders | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Emmanuel Carrera | 1 |
| Cukurova University | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| National Taiwan University Hospital | 1 |
| Mansoura University | 1 |
| Assiut University | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
10 current trials in our Belgium, Canada, Egypt, Spain, Italy, Sweden, Poland, Netherlands, Switzerland, Turkey and Taiwan registers name Mannitol as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 10 trials are recruiting: 2 with sites in Belgium, 2 with sites in Canada, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Sweden, 1 with sites in Poland, 1 with sites in Netherlands, 1 with sites in Switzerland and 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
NTC srl (1), dr. M.J.N.L. Benders (1), Universitaire Ziekenhuizen KU Leuven (1) and Emmanuel Carrera (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 4 single-substance products containing Mannitol, for example Mannitol 10% Solution for Infusion BP (Baxter Holding B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 1 entry for Mannitol: Bronchitol (EU: shortage ongoing). Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mannitol works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mannitol works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mannitol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.